What does the new PreferCo-Glatt partnership mean for precision fermentation scale-up?
PreferCo, a bioprocessing consultancy, has partnered with German process technology leader Glatt to establish a Center of Excellence (CoE) in Hyderabad focused on precision fermentation bioprocess scale-up. The facility will combine Glatt's 150+ years of process technology expertise with PreferCo's bioprocessing capabilities to address the critical bottleneck of transitioning precision fermentation from lab-scale to commercial production.
The partnership targets the growing precision fermentation market, which reached $2.8 billion in 2025 and faces significant scale-up challenges. Traditional fermentation processes often fail when moving from 10L lab reactors to 50,000L+ commercial bioreactors, with yield losses of 30-60% common during scale-up. The new CoE will provide integrated solutions spanning upstream cell line development through downstream processing optimization.
This partnership reflects the industry's recognition that bioprocess engineering expertise has become as critical as strain engineering for commercial success in precision fermentation. Companies like Perfect Day and Solugen have demonstrated that manufacturing excellence often determines market viability more than novel biology alone.
Strategic Location and Market Positioning
The Hyderabad location positions the CoE within India's growing bioeconomy, which the government aims to expand to $300 billion by 2030. India's lower operational costs - typically 40-50% below European equivalents for bioprocessing services - make it attractive for precision fermentation companies seeking to optimize manufacturing economics.
Glatt brings significant process technology credentials, including expertise in fluid bed processing, spray drying, and continuous manufacturing systems. Their equipment portfolio includes specialized bioreactors and purification systems designed for microbial fermentation applications.
PreferCo contributes bioprocessing consulting expertise, particularly in strain optimization and fermentation parameter tuning. The company has worked with multiple precision fermentation startups on scale-up challenges, though specific client names and project details remain confidential.
Addressing Industry Scale-Up Bottlenecks
The precision fermentation industry faces several critical scale-up challenges that the new CoE aims to address:
Process Transfer Inefficiencies: Moving from shake flasks to production-scale fermenters often requires complete process re-optimization. Parameters like oxygen transfer rates, mixing patterns, and temperature gradients change dramatically with scale.
Strain Performance Degradation: Engineered microorganisms that perform well in controlled lab conditions frequently show reduced productivity in large-scale environments due to stress factors and population heterogeneity.
COGS Optimization: Commercial viability requires achieving cost structures competitive with traditional chemical production. This demands optimization across feedstock utilization, energy consumption, and purification efficiency.
The CoE will offer integrated services spanning these challenges, from initial process assessment through pilot-scale validation and technology transfer to commercial facilities.
Market Context and Competition
The precision fermentation scale-up services market has attracted significant investment, with companies like National Resilience raising $800 million specifically for biomanufacturing infrastructure. However, most existing facilities focus on biologics production rather than precision fermentation for food, materials, and chemicals.
European competitors include DSM's bioprocessing services division and Novozymes' fermentation capabilities, but these primarily serve established enzyme and specialty chemical markets rather than emerging precision fermentation applications.
The Asia-Pacific region represents a strategic growth market for precision fermentation, driven by regulatory support and lower manufacturing costs. Singapore has committed $90 million to alternative protein infrastructure, while Thailand is developing specialized bioprocessing zones.
Technology Integration and Capabilities
The CoE will integrate multiple technology platforms:
Upstream Processing: Strain optimization, media development, and fermentation parameter tuning using Glatt's advanced monitoring and control systems.
Fermentation Systems: Pilot-scale bioreactors ranging from 100L to 5,000L capacity, enabling systematic scale-up studies and process validation.
Recovery and Purification: Downstream processing equipment including centrifuges, chromatography systems, and specialized drying technologies for different product formats.
Process Analytics: Real-time monitoring systems for critical quality attributes and process performance indicators.
The facility will also provide regulatory support for companies seeking approval in various markets, particularly important for food-grade precision fermentation products.
Industry Implications
This partnership signals the maturation of precision fermentation from a research field to an industrial sector requiring specialized manufacturing expertise. The establishment of dedicated scale-up facilities outside traditional biopharmaceutical hubs reflects the unique requirements of precision fermentation applications.
The geographic diversification of bioprocessing capabilities also reduces supply chain risks for precision fermentation companies, which have historically been concentrated in North America and Western Europe. India's growing role mirrors broader trends in biotechnology manufacturing, where cost optimization drives geographic distribution.
For investors, the partnership validates the commercial opportunity in precision fermentation services. The sector's capital intensity has created opportunities for specialized service providers rather than requiring each company to build internal manufacturing capabilities.
Frequently Asked Questions
What specific services will the PreferCo-Glatt CoE provide?
The Center of Excellence will offer integrated bioprocess development services including strain optimization, fermentation scale-up, downstream processing design, and technology transfer support. Services span from initial process assessment through pilot-scale validation and commercial manufacturing support.
Why is Hyderabad strategically important for this partnership?
Hyderabad offers 40-50% lower operational costs compared to European facilities while providing access to skilled biotechnology talent and government support for bioeconomy development. The location also serves emerging Asian precision fermentation markets.
How does this partnership address precision fermentation scale-up challenges?
The CoE combines Glatt's process technology expertise with PreferCo's bioprocessing knowledge to tackle common scale-up issues like yield losses during process transfer, strain performance degradation, and cost optimization for commercial viability.
What types of companies will benefit from these services?
The facility targets precision fermentation companies developing products across food ingredients, specialty chemicals, materials, and pharmaceuticals that need to transition from laboratory-scale to commercial manufacturing.
How does this compare to existing bioprocessing service providers?
Unlike traditional biologics-focused CDMOs, this CoE specifically targets precision fermentation applications, which have different requirements for feedstocks, processing conditions, and product characteristics.
Key Takeaways
- PreferCo and Glatt establish specialized CoE in Hyderabad for precision fermentation scale-up services
- Partnership addresses critical industry bottleneck of transitioning from lab to commercial production
- India location offers 40-50% cost advantages while accessing growing Asian bioeconomy markets
- Integrated services span strain optimization through downstream processing and technology transfer
- Reflects maturation of precision fermentation from research field to industrial manufacturing sector
- Geographic diversification reduces supply chain risks for precision fermentation companies
- Validates commercial opportunity in specialized bioprocessing services for emerging biotechnology applications